Drug Database
UN

unspecified allergy vaccine (Staloral)

✓ Approved

Stallergenes · therapeutic agent

What is unspecified allergy vaccine?

unspecified allergy vaccine is a therapeutic agent developed by Stallergenes. It is approved for therapeutic indications via injectable (others) or oral (po) or subcutaneous injection or sublingual (sl)/oral transmucosal.

Drug Profile

Brand NamesStaloral
CompanyStallergenes
RouteInjectable (Others), Oral (PO), Subcutaneous Injection, Sublingual (SL)/Oral Transmucosal
StatusApproved
Sources: ClinicalTrials.gov, Stallergenes

Therapeutic Indications

unspecified allergy vaccine is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Respiratory, thoracic and mediastinal disordersAsthma✓ Approved
Respiratory, thoracic and mediastinal disordersRhinitis allergic✓ Approved

Related Research Articles

PubMedCureus2026-07-17

Unravelling the Allergy Label: A Case of Successful Multi-drug Allergy De-labelling in a Patient.

Vassila Angeliki A, Teo Ying Y, Jones Michael A MA

We report the case of a 23-year-old woman with a pre-existing penicillin allergy label from childhood who presented with severe bilateral conjunctivitis and oral mucositis following a prodromal respiratory illness. Her symptoms worsened shortly after receiving doxycycline, raising concern for a drug reaction. Her condition progressed with significant ocular involvement requiring bilateral amniotic membrane grafting and subsequent immunosuppressive therapy. Investigations confirmed Mycoplasma pneumoniae infection, supporting a diagnosis most consistent with Mycoplasma-induced rash and mucositis (MIRM), although Stevens-Johnson syndrome (SJS) could not be fully excluded. Following recovery, a structured allergy work-up was undertaken, including patch testing, intradermal testing and graded oral provocation in accordance with established guidance. All tests were negative, and the patient successfully tolerated amoxicillin, doxycycline and ibuprofen without adverse reactions. This case demonstrates how a structured, multidisciplinary approach to drug allergy evaluation can facilitate de-labelling in patients with complex mucocutaneous presentations, restore access to first-line therapies and improve patient care.

PMID 42465146
Read full article →
PubMedClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026-07-17

Artificial Intelligence Across the Vaccine Clinical Trial Lifecycle: Evidence, Readiness, and Guardrails.

Idriss Jad J, Kalash Suha S, Faraj Jana Abu JA, Nolan Lauren L et al.

Artificial intelligence (AI) is increasingly being used to support clinical research, but its value in vaccine clinical trials requires careful evidence-based assessment. Vaccine trials pose distinctive challenges, including high safety expectations in healthy participants, evolving pathogen exposure and baseline immunity, incomplete correlates of protection, applicability of findings to intended-use populations, and intense public scrutiny. We conducted a structured, vaccine-focused narrative review of AI applications across the vaccine trial lifecycle, supplemented by targeted clinical trial and vaccine pharmacovigilance studies with directly transferable methods. In the combined evidence base, evidence is strongest for operational uses, particularly recruitment, eligibility screening, trial matching, and risk-based monitoring. Applications to immune-response interpretation, correlates of protection, and vaccine safety surveillance are promising but remain less prospectively validated. Responsible adoption should be guided by intended tool use, evidence of strength, data governance, regulatory expectations, and preservation of human scientific and safety judgment.

PMID 42464875
Read full article →
PubMedIranian journal of nursing and midwifery research2026-07-17

Investigate the Relationship Between Receiving the COVID-19 Vaccine and Menstrual Disorders among Females of Reproductive Age in Jeddah, Saudi Arabia.

Esheaba Ola M OM, Fouly Howieda A HA, Kassem Fathia K FK

There are many physical side effects of the COVID-19 vaccine, including unexpected changes occurring in menstrual bleeding. This study aimed to assess the relation between the COVID-19 vaccine and disorders in menstruation among females of reproductive age. Participants were recruited from a nonprobability snowball sampling targeted at females who are living in Jeddah city between March 2022 and August 2022, Kingdom of Saudi Arabia (KSA). A quantitative cross-sectional design was utilized to conduct the study, a nonexperimental design based on a single observation point. The sample size is estimated by the G*Power software to be 180, considering missed cases, it increased to 197. Regarding menstrual changes, n = 86 (43.65%) experienced a delay, and about one-third reported an earlier menstruation cycle. A significant relationship is observed between nationality, occupation, and changes in period (t = 3.89, P < 0.001 and t = -2.94, P < 0.004). There is no significant difference in the occurrence of complications among the different vaccine types. Receiving the COVID-19 vaccine was strongly linked with unexpected disturbance in menstruation among the studied group, from simple menstrual irregulates to reported amenorrhea after receiving the booster doses. However, the occurrence of menstrual cycle delays was not linked to the vaccine type. Further studies should be done to investigate each type of vaccine specifically to determine if the type of vaccine affects the reproductive function generally not only the menstrual cycle, in a larger survey for more generalizability.

PMID 42466287
Read full article →
PubMedFrontiers in public health2026-07-17

Reframing vaccine narrative: a co-production study of a media campaign intervention to address childhood vaccine hesitancy among Nigerian parents and caregivers.

Ike Tarela Juliet TJ, Jidong Dung Ezekiel DE, Obi Callistar Kidochukwu CK, Ntaji Maureen Iru MI et al.

Childhood vaccine hesitancy is a public health concern. Nigeria is one of the countries with the highest rates of zero-dose childhood vaccination. This study makes an original contribution by adopting a co-production approach underpinned by interpretative phenomenological analysis (IPA) to meaningfully inform the co-production of a media campaign intervention with Nigerian parents/ caregivers whose child(ren) are not, or only partially, up to date with routine immunizations aimed at reducing childhood vaccine hesitancy and promoting uptake. A total of 10 parents or caregivers whose children were not up to date with their vaccinations were recruited for the study and participated in a focus group discussion. Data were analyzed using IPA. The findings reveal that hostility, misinformation, and the breakdown of trust in vaccines, alongside faith, tradition, and the lived logic of alternative protection, intersect to exacerbate hesitancy. The findings also reveal that clarity, reassurance, and empowerment in vaccine communication, underpinned by gendered voices, can build trust in vaccine messaging and encourage uptake. The study offers important insights for policymakers and public health communication strategies, underscoring the need for culturally appropriate media campaign interventions that address vaccine-related concerns and foster uptake.

PMID 42465634
Read full article →
PubMedCureus2026-07-17

Surgical Management of Choledocholithiasis in a Patient After Bariatric Surgery at a Rural Hospital.

Moberly Atley A, Moore Shane S, Monnett Shane S

Choledocholithiasis is a serious complication of gallstone disease, and its management can be challenging in patients with altered gastrointestinal anatomy following bariatric surgery. We report the case of a 73-year-old woman with a history of unspecified bariatric surgery who presented with abdominal pain and evidence of a 14-mm common bile duct stone and ductal dilation. Initial endoscopic retrograde cholangiopancreatography (ERCP) was unsuccessful due to altered anatomy and an inability to traverse the duodenojejunal limb. In a rural hospital without advanced endoscopic options, open common bile duct exploration (OCBDE) was performed, successfully removing the stone. The patient recovered without complications. This case highlights the limitations of ERCP in post-bariatric surgery patients and the continued importance of OCBDE as a definitive, potentially lifesaving intervention in resource-limited or rural environments.

PMID 42465167
Read full article →
PubMedVaccine2026-07-17

Protective immunity of lectin-adjuvanted intraperitoneal injection vaccine against Aeromonas veronii infection in Oreochromis niloticus.

Guha Ritam R, Wangkahart Eakapol E, Elumalai Preetham P

Disease outbreaks caused by Aeromonas veronii pose a significant threat to Nile tilapia (Oreochromis niloticus) aquaculture. Lectin-based adjuvants, such as concanavalin A (ConA), can potentially enhance vaccine efficacy by stimulating both innate and adaptive immunity. This study evaluated the immunoprotective potential of a ConA-adjuvanted, formalin-inactivated A. veronii vaccine administered intraperitoneally. Nile tilapia were vaccinated intraperitoneally with the inactivated A. veronii vaccine formulated with ConA. Safety was assessed by monitoring fish behavior and physiological responses. Innate immune activation was evaluated through lysozyme (LZM), myeloperoxidase (MPO), and superoxide dismutase (SOD) assays. Humoral response was measured via serum IgM levels. Gene expression in head kidney and spleen tissues was analyzed for TCR-β, IgM, MHC -II, CD4, and proinflammatory cytokines (IL-1β, IL-8). Protective efficacy was determined by challenging vaccinated fish with live A. veronii and calculating relative percent survival (RPS). The vaccine was safe, with no adverse effects observed. Vaccinated fish showed significant increases in LZM, MPO, and SOD activities, indicating enhanced innate immunity. Serum IgM levels peaked at 42 days post-vaccination, demonstrating robust humoral response. Gene expression analysis revealed upregulation of immune markers confirming activation of humoral (IgM), proinflammatory cytokine (IL-1β, IL-8) and cell-mediated pathways (TCR-β, MHC-II, CD4). Following challenge, the ConA-adjuvanted vaccine group exhibited the highest RPS (79%), significantly higher than controls. These results highlight the potent immunostimulatory effect of ConA and the vaccine's capacity to bridge innate and adaptive immunity in Nile tilapia. The adjuvant effects of ConA have improved the vaccine efficacy and immunogenicity.

PMID 42462678
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about unspecified allergy vaccine